✦ LIBER ✦

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control

✍ Scribed by V. Thornton; D. Lennon; K. Rasanathan; J. O’Hallahan; P. Oster; J. Stewart; S. Tilman; I. Aaberge; B. Feiring; H. Nokleby; E. Rosenqvist; K. White; S. Reid; K. Mulholland; M.J. Wakefield; D. Martin

Book ID: 116958475
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 123 KB
Volume: 24
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2005.09.043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity and safety of a strain-sp

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

✍ P. Oster; J. O’Hallahan; I. Aaberge; S. Tilman; E. Ypma; D. Martin 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 244 KB

Safety and immunogenicity of a new Neiss

Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults

✍ Peter Richmond; David Goldblatt; Peter C Fusco; Joan D.S Fusco; Iver Heron; Sara 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Safety, immunogenicity, and antibody per

Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults

✍ Nilima Kshirsagar; Naidu Mur; Urmila Thatte; Nithya Gogtay; Simonetta Viviani; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 696 KB

Immunogenicity and tolerability of a mul

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

✍ María Elena Santolaya; Miguel L O'Ryan; María Teresa Valenzuela; Valeria Prado; 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 265 KB

Re: Immunogenicity and safety of a strai

Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O’Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075–9

✍ Diana Lennon 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Response to the letter written by Profes

Response to the letter written by Professor Lennon (dated April 27, 2007) regarding our publication: “Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand” by Oster P, O’Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D (Vaccine 2007;25(16):3075–79)

✍ P. Oster; J. O’Hallahan; I. Aaberge; S. Tilman; E. Ypma; D. Martin 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 86 KB